EP3045156A1 - Lentille de contact de réticulation de correction de la cornée - Google Patents

Lentille de contact de réticulation de correction de la cornée Download PDF

Info

Publication number
EP3045156A1
EP3045156A1 EP15834663.5A EP15834663A EP3045156A1 EP 3045156 A1 EP3045156 A1 EP 3045156A1 EP 15834663 A EP15834663 A EP 15834663A EP 3045156 A1 EP3045156 A1 EP 3045156A1
Authority
EP
European Patent Office
Prior art keywords
cornea
contact lens
region
lens
pressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15834663.5A
Other languages
German (de)
English (en)
Other versions
EP3045156B1 (fr
EP3045156A4 (fr
Inventor
Iwane Mitsui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP3045156A1 publication Critical patent/EP3045156A1/fr
Publication of EP3045156A4 publication Critical patent/EP3045156A4/fr
Application granted granted Critical
Publication of EP3045156B1 publication Critical patent/EP3045156B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G02—OPTICS
    • G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C7/00—Optical parts
    • G02C7/02—Lenses; Lens systems ; Methods of designing lenses
    • G02C7/04—Contact lenses for the eyes
    • G02C7/047—Contact lens fitting; Contact lenses for orthokeratology; Contact lenses for specially shaped corneae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/0079—Methods or devices for eye surgery using non-laser electromagnetic radiation, e.g. non-coherent light or microwaves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/013—Instruments for compensation of ocular refraction ; Instruments for use in cornea removal, for reshaping or performing incisions in the cornea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • G—PHYSICS
    • G02—OPTICS
    • G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C7/00—Optical parts
    • G02C7/02—Lenses; Lens systems ; Methods of designing lenses
    • G02C7/04—Contact lenses for the eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet

Definitions

  • the present invention relates to a contact lens for cornea-correction crosslinking that changes a shape of the cornea of a patient while being mounted for a given period of time, and allows, in a state of correcting myopia, hyperopia, or keratoconus cornea, infiltration of a riboflavin (vitamin B2) solution into a corneal tissue and ultra-violet ray irradiation for crosslinking collagens constituting the cornea to one another, thereby enhancing strength of the cornea and fixing thereof.
  • a contact lens for cornea-correction crosslinking that changes a shape of the cornea of a patient while being mounted for a given period of time, and allows, in a state of correcting myopia, hyperopia, or keratoconus cornea, infiltration of a riboflavin (vitamin B2) solution into a corneal tissue and ultra-violet ray irradiation for crosslinking collagens constituting the cornea to one another, thereby enhancing strength of the cornea and fixing thereof.
  • a contact lens for changing the shape of the cornea of a patient by being mounted during sleep and the like, and correcting myopia, hyperopia, and/or astigmatism at the time when the contact lens is removed.
  • a riboflavin solution is dropped from a cylindrical reservoir unit mounted on the cornea so as to be infiltrated into the cornea.
  • Patent Literature 1 the present inventor proposed a contact lens for cornea-correction crosslinking and a cornea-correction crosslinking method.
  • This method is intended to fix the shape of a cornea to some extent in a state of being corrected by a contact lens by combining a crosslinking method and a cornea-correction contact lens.
  • Patent Literature 1 Japanese Patent Application Laid-Open No. 2015-36080
  • An object of the present invention is to provide a contact lens for cornea-correction crosslinking that allows, while being mounted on a patient, infiltration of a riboflavin solution into the cornea in a short time and ultraviolet-ray irradiation for crosslinking the cornea.
  • a contact lens for cornea-correction crosslinking with a reservoir portion capable of storing a riboflavin solution for cornea-correction crosslinking, an operation-side electrode having the same polarity as that of the riboflavin solution, the electrode being provided at a position in contact with the riboflavin solution in the reservoir portion, and a communication hole for guiding the riboflavin solution in the reservoir portion to the inside of the lens, the riboflavin solution can be infiltrated quickly and surely by iontophoresis and also ultraviolet-rays can be irradiated while the contact lens remains mounted on the cornea, that is, in a state in which the cornea is being corrected.
  • a riboflavin solution can be surely infiltrated into the cornea of a patient in a short time while the contact lens remains mounted on the cornea, that is, in a state in which the cornea is being corrected.
  • a relief region constituted by a concave portion and a pressing region constituted by a convex portion are formed on a side of the lens in contact with the cornea of a patient.
  • a part of the cornea is pushed downward and, as a reaction thereof, a part of the cornea is projected into the relief region, so that the cornea is corrected into a shape in which desirable naked eye vision can be obtained or a shape in which keratoconus cornea is smoothly suppressed.
  • a curvature of the curve of the convex portion or the concave portion is set anticipating this return.
  • a riboflavin solution in a reservoir portion is allowed to infiltrate into the cornea from the outside of the contact lens via a communication hole provided so as to penetrate the contact lens by an action of iontophoresis, and also the cornea is irradiated with ultra-violet rays via the contact lens after infiltration.
  • An operation-side electrode has the same polarity as that of the riboflavin solution, thus when a DC current is applied, the riboflavin solution is repelled from the operation-side electrode, and also sucked by a non-operation-side electrode, resulting in infiltrating into the cornea.
  • the present invention is also applied to the case where a return of corneal deformation due to spring back of the eyeball (elastically restoring force) is not anticipated.
  • a contact lens is changed stepwise so as to correct eyesight to a desired level.
  • the riboflavin solution is allowed to infiltrate and, ultra-violet rays are irradiated to the cornea via the contact lens while that state is maintained.
  • the above-described concave curved-surface of curvature R 0 is formed by the pressing region having the convex curved-surface of curvature R 0 .
  • D represents diopter as a unit for indicating refractivity of the eye.
  • the above-mentioned values from + 5.0D to + 10.0D are a correction amount obtained by taking into consideration corneal deformation based on elastically restoring force of the eyeball after crosslinking, and deduced from a large number of treatment cases performed by the inventor. It is noted that it was not conventionally known that corneal deformation after crosslinking is caused by elastically restoring force of the eyeball until the inventor has found it.
  • the outer diameter D 1 of a peripheral portion be set larger than the average outer diameter Do of the outer periphery of the human cornea by 3.0 mm to 5.0 mm, and a UV-shielding membrane for shielding UV rays is provided to the lens in an annular region, on a side in contact with the cornea, from a position having a diameter of D 0 -3.0 mm to D 0 -5.0 mm to the outermost periphery in the outer peripheral portion.
  • a material of the UV-shielding membrane for shielding ultraviolet rays a material harmless to the cornea, for example, a gold thin film, a titanium thin film, a silver thin film, and the like may be used.
  • UV-shielding membrane When the UV-shielding membrane is provided outside the contact lens, ultra-violet rays incident from the central area of the contact lens are reflected/diffracted inside and sometimes reach the outer periphery of the cornea. Thus the UV-shielding membrane is provided on a side in contact with the cornea.
  • a contact lens for cornea-correction crosslinking (hereinafter referred to as a contact lens) 30 for correcting myopia according to Example 1 of the present invention is used by being mounted on a cornea 2.
  • the contact lens 30 is configured to include: a pressing region 32 formed to project in a convex curved-surface shape at a position corresponding to the center of a corneal dome (a front end surface of the cornea 2 having the most protruding portion) to be pressed; a relief region 34 constituted by an annular concave portion having a cross section in a concave circular arc shape, the relief region 34 being formed at a position encircling the outer periphery of the pressing region 32; an anchor region 38 having a shape aligned with a contour 36 (see Fig.
  • the anchor region 38 being provided at a position encircling the outer periphery of the relief region 34; and a peripheral portion 40 encircling the outer periphery of the anchor region 38.
  • a reservoir portion 12 is composed of a material that is not liberated in a riboflavin solution even when a current is allowed to flow
  • an operation-side electrode 14 is composed of a strip-shaped conductive material such as a gold thin film or a conductive resin, formed in a cylindrical shape on the inner peripheral surface of the reservoir portion 12.
  • a non-operation-side electrode 16 is composed of a conductive rubber, for example, and adhered to the skin of a human body by a conductive adhesive, allowing the passage of a current.
  • the operation-side electrode 14 has the same polarity as that of the riboflavin solution. Cation is used in Example.
  • the cornea 2 is shown in a state of being corrected by the contact lens 30.
  • a cornea infiltration device 10 is provided on the outside (the opposite side of an eyeball 1) of the contact lens 30.
  • the cornea infiltration device 10 is configured to include: the cylindrical reservoir portion 12 disposed outside of the contact lens 30 so as to correspond to the central area of the cornea 2 of the eyeball 1 of a patient; the operation-side electrode 14 formed on the inner peripheral surface of the reservoir portion 12; the non-operation-side electrode 16 adhered to the skin of the patient in the vicinity of the eyeball 1; and a battery 13A and a switch 13B disposed between the operation-side electrode 14 and the non-operation-side electrode 16.
  • Reference numerals 3 and 19 in Fig. 1 denote the crystalline lens and a syringe for dropping a riboflavin solution from above the reservoir portion 12, respectively.
  • a tip (a lower end in Fig. 1 ) of the cylindrical reservoir portion 12 is connected and mounted on the outside of the contact lens 30.
  • communication holes 44 for communicating the inside of the reservoir portion 12 with the pressing region 32 are provided to the contact lens 30 on the same virtual circle encircling the center of the contact lens 30 (a lens center) at equal intervals (equal angular intervals of 45°C) at four points so as to penetrate the pressing region 32 in a thickness direction of the lens.
  • a conventional contact lens (hereinafter referred to as a conventional lens) 5A for correcting myopia is shown by a two-dot chain line.
  • This conventional contact lens 5A for correcting myopia includes a pressing region (with a convex curved-surface of curvature R 0 ) for forming a concave curved-surface of curvature R 0 in order to obtain a targeted naked eye vision of a patient.
  • the pressing region 32 is projected towards a direction of the cornea 2 in contrast to the conventional lens 5A, and conversely the relief region 34 forms a deeper annular concave portion than a relief region 6A of the conventional lens 5A.
  • the peripheral portion 40 is larger than a peripheral portion of the conventional lens 5A and extended along the contour 36 of the cornea 2.
  • R s a curvature of the convex curved-surface of the pressing region 32 in Example 1
  • R 0 a curvature of the convex curved-surface of the conventional lens 5A
  • the aforementioned curvature R 0 is a curvature of a concave curved-surface to be formed on the cornea 2 for correcting at least one of naked eye vision and keratoconus cornea of a patient.
  • the reason R s is set to satisfy R s > R 0 is that when the cornea of a patient is pressed by the pressing region having a convex curved-surface of curvature R 0 and then the pressing is released, the cornea is deformed so as to lessen a curvature of the concave curved-surface at the central area of the corneal dome due to elastically restoring force (spring back) of the eyeball, thus R s is set anticipating this spring back amount.
  • this spring back amount is defined as ⁇ R
  • an outer diameter D 1 of the peripheral portion 40 of the contact lens 30 is set larger than an average outer diameter D 0 of the outer peripheral edge of the human cornea by 3.0 mm to 5.0 mm, and a UV-shielding membrane 42 for shielding ultraviolet rays is provided to the lens in an annular region, on a side in contact with the cornea, from a position having a diameter of D 0 -3.0 mm to D 0 -5.0 mm to the outermost periphery in the peripheral portion 40.
  • the UV-shielding membrane 42 is preferably made of a material that is harmless even when being in contact with the cornea 2, including, for example, a thin film of gold, titanium, silver, and the like.
  • the peripheral portion 40 of the cornea 2 is not damaged by ultra-violet ray irradiation during crosslinking, thus pluripotent cells for regenerating the cornea can be preserved.
  • the contact lens 30 having the cornea infiltration device 10 attached to the outside of the contact lens is mounted on the cornea 2 of a patient, and the cornea 2 is corrected along the shapes of the pressing region 32 and the relief region 34 located inside the contact lens 30.
  • a riboflavin solution is injected into the reservoir portion 12, and subsequently, a current is supplied between the operation-side electrode 14 and the non-operation-side electrode 16 from the battery 13A.
  • the riboflavin solution Since the riboflavin solution has the same polarity as that of the operation-side electrode 14, the riboflavin solution is repelled andmoves in a direction of the non-operation-side electrode 16, that is, a direction of the cornea 2 by the action of iontophoresis.
  • the riboflavin solution in the reservoir portion 12 readily reaches the surface of the cornea 2 through the communication holes 44, and then infiltrates into the cornea 2.
  • the cornea 2 After the cornea 2 is infiltrated with the riboflavin solution, the cornea 2 is irradiated with ultra-violet rays in this state via the contact lens 30, thereby crosslinking collagen fibers that constitute the cornea 2.
  • the reservoir portion 12 is formed in a hollow cylindrical shape, ultra-violet ray irradiation can be performed even when the reservoir portion 12 remains attached to the contact lens 30.
  • the UV-shielding membrane 42 is formed on the contact lens 30 on a side in contact with the cornea 2 so as to cover the peripheral portion 40, thus ultra-violet rays do not reach the cornea 2. Thus, pluripotent cells of the cornea 2, localized inside the peripheral portion 40, are not damaged.
  • the cornea 2 is fixed in the same shape as conferred by the pressing region 32 and the relief region 34.
  • the central area of the cornea 2 is projected due to elastically restoring force of the eyeball.
  • the curvature R s of the convex curved-surface of the pressing region 32 is set anticipating the spring back amount in advance, a curvature of the concave curved-surface formed on the cornea 2 comes to R 0 after spring back.
  • a contact lens 130 for correcting hyperopia according to Example 2 shown in Fig. 3 , will be described.
  • a conventional contact lens 5B for correcting hyperopia is shown by a two-dot chain line.
  • the contact lens 130 for correcting hyperopia according to Example 2 has a configuration in which a concave part and a convex part are switched between the pressing region and the relief region as compared to the contact lens 30 shown above in Fig. 1 .
  • a relief region 134 is formed in a concave curved-surface shape at a position corresponding to the central area of a corneal dome to be in contact with when the lens 130 is mounted on the cornea 2, and a pressing region 132 is constituted by an annular convex portion having a cross section in a convex circular arc shape and formed at a position encircling the outer periphery of the relief region 134.
  • an anchor region 138 is provided at a position encircling the outer periphery of the pressing region 132 and formed into a shape aligned with a contour 136 (see Fig. 4 ) of the cornea when the lens 130 is mounted on the cornea 2.
  • a peripheral portion 140 is configured so as to encircle the outer periphery of the anchor region 138.
  • Reference numeral 142 in Fig. 3 denotes a UV-shielding membrane.
  • a total of nine communication holes 144 penetrating the contact lens 130 for correcting hyperopia in a thickness direction thereof are formed between the inside of the reservoir portion 12 and the cornea 2 surface.
  • a central communication hole 144A having a larger inner diameter is provided at the central position of the contact lens 130 for correcting hyperopia, and four intermediate communication holes 144B and four outside communication holes 144C are formed on two concentric circles surrounding the central communication hole 144A, respectively (see Fig. 4 ).
  • the intermediate communication holes 144B are provided inside the relief region 134, at positions adjacent to the lens center side of the pressing region 132, and the outside communication holes 144C are provided at positions adjacent to a side (the outside) opposite to the lens center of the pressing region 132.
  • Both the intermediate communication holes 144B and the outside communication holes 144C may be provided at a plurality of, three or more, points at equal intervals. Further, when the intermediate communication holes 144B are provided inside the pressing region 132, the outside communication holes 144C may not be provided.
  • the value is a correction amount obtained by taking into consideration a spring back amount ⁇ r due to elastically restoring force of the eyeball at the central area of the corneal dome after releasing the pressing force of the contact lens 130 for correcting hyperopia, deduced from a large number of treatment cases performed by the inventor.
  • crosslinking is performed to the corrected cornea using the contact lens 130 for correcting hyperopia
  • crosslinking is performed through the same process as for the contact lens 30 for correcting myopia according to the aforementioned Example 1.
  • the present invention can be used as a contact lens for cornea-correction crosslinking, allowing quick and sure infiltration of a riboflavin solution when the cornea is fixed by crosslinking in a state in which a shape of the cornea is corrected by the contact lens.

Landscapes

  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Electromagnetism (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Eyeglasses (AREA)
  • Electrotherapy Devices (AREA)
EP15834663.5A 2014-10-10 2015-10-07 Lentille de contact de réticulation de correction de la cornée Active EP3045156B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014209471 2014-10-10
JP2015110788A JP5828535B1 (ja) 2014-10-10 2015-05-29 矯正角膜クロスリンキング用コンタクトレンズ
PCT/JP2015/078442 WO2016056575A1 (fr) 2014-10-10 2015-10-07 Lentille de contact de réticulation de correction de la cornée

Publications (3)

Publication Number Publication Date
EP3045156A1 true EP3045156A1 (fr) 2016-07-20
EP3045156A4 EP3045156A4 (fr) 2017-07-26
EP3045156B1 EP3045156B1 (fr) 2018-08-22

Family

ID=54784321

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15834663.5A Active EP3045156B1 (fr) 2014-10-10 2015-10-07 Lentille de contact de réticulation de correction de la cornée

Country Status (5)

Country Link
US (1) US9664926B2 (fr)
EP (1) EP3045156B1 (fr)
JP (1) JP5828535B1 (fr)
TW (1) TWI653038B (fr)
WO (1) WO2016056575A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4273619A1 (fr) * 2022-05-04 2023-11-08 Pauné Fabré, Jaime Lentille de contact orthokératologique

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
JP5996544B2 (ja) 2010-10-15 2016-09-21 クリアサイド・バイオメディカル・インコーポレーテッドＣｌｅａｒｓｉｄｅ Ｂｉｏｍｅｄｉｃａｌ Ｉｎｃｏｒｐｏｒａｔｅｄ 眼球アクセス用装置
WO2013149075A1 (fr) 2012-03-29 2013-10-03 Cxl Ophthalmics, Llc Compositions et procédés de traitement ou de prévention de maladies associées au stress oxydatif
EP4420725A3 (fr) 2012-03-29 2025-04-16 Epion Therapeutics, Inc. Solutions de traitement oculaire, dispositifs d'administration et procédés améliorant l'administration
BR112015027762A2 (pt) 2013-05-03 2017-08-29 Clearside Biomedical Inc Aparelho e métodos para injeção ocular
AU2016379263A1 (en) * 2015-12-22 2018-07-19 Mitsui Medical Commerce Co., Ltd. Contact lens for corrective corneal crosslinking and method for producing same
EP3452165A1 (fr) 2016-05-02 2019-03-13 Clearside Biomedical, Inc. Systèmes et méthodes pour l'administration de médicaments par voie ophtalmique
IL305537B2 (en) 2016-08-12 2025-02-01 Clearside Biomedical Inc Devices and methods for adjusting the insertion depth of a needle for administering a drug
WO2020028829A1 (fr) * 2018-08-02 2020-02-06 University Of Florida Research Foundation Méthodes et compositions pour l'administration par ionophorèse d'un médicament en direction de l'œil
CN110367927B (zh) * 2019-08-01 2022-04-08 中山大学 青光眼眼压连续检测系统及其检测方法
KR102077579B1 (ko) * 2019-08-14 2020-02-14 이정훈 각막굴절교정용 렌즈
KR200493960Y1 (ko) * 2020-02-07 2021-07-08 이정훈 각막굴절교정용 렌즈
CN112305782A (zh) * 2020-10-15 2021-02-02 杭州涉吉光学有限公司 用于矫正青少年近视的角膜塑形镜
EP4529903A1 (fr) * 2022-07-08 2025-04-02 Terumo Kabushiki Kaisha Dispositif d'administration de médicament intraoculaire, réservoir d'agent et procédé de fonctionnement d'un dispositif d'administration de médicament intraoculaire
EP4565918B1 (fr) * 2022-10-19 2025-12-17 CooperVision International Limited Lentilles de contact orthokératologiques et procédés associés
CN119279912B (zh) * 2024-11-27 2025-07-15 艾普柯(成都)医疗科技有限公司 眼表用生物膜固定装置及眼表修复装置

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270051A (en) * 1991-10-15 1993-12-14 Harris Donald H Enzyme-orthokeratology
JPH09266954A (ja) * 1996-04-03 1997-10-14 Meiwa Shoji Kk 電極付治療器具
US6010219A (en) * 1996-06-28 2000-01-04 Contex, Inc. Fenestrated contact lens for treating myopia
JP3044891U (ja) 1997-06-30 1998-01-16 株式会社ホーマーイオン研究所 浴槽用通電治療器
FR2773320B1 (fr) * 1998-01-05 2000-03-03 Optisinvest Dispositif pour le transfert intraoculaire de produits actifs par iontophorese
JP3881221B2 (ja) * 2001-11-16 2007-02-14 石根 三井 近視および／または乱視矯正用コンタクトレンズ
US7559649B2 (en) * 2005-01-12 2009-07-14 Dakota Sciences, LLC Corneal-scleral orthokeratology contact lens
AU2008347866A1 (en) * 2008-01-16 2009-07-23 Tokuichiro Hasegawa Vision corrective jig and cooling fluid injection tool for the jig
US8500273B2 (en) * 2008-06-06 2013-08-06 Global-Ok Vision, Inc. Soft contact lenses for treating ametropia
JP2012502668A (ja) * 2008-09-19 2012-02-02 アヴェドロ・インコーポレーテッド 眼治療システム
US20100318017A1 (en) * 2009-06-11 2010-12-16 Lewis Scott E Method of improving vision using contact lenses and corneal collagen crosslinking
AU2011210536A1 (en) * 2010-02-01 2012-09-13 Conversion Energy Enterprises Inc. Methods and devices for crosslinking of corneal collagen and for treatment of disorders of the eye
US20110237999A1 (en) * 2010-03-19 2011-09-29 Avedro Inc. Systems and methods for applying and monitoring eye therapy
WO2011163574A1 (fr) * 2010-06-25 2011-12-29 Dewoolfson Bruce H Dispositif et procédé d'administration contrôlée de solutions ophtalmiques
AU2011355093B2 (en) * 2011-01-12 2015-11-26 Sooft Italia Spa Device and method for corneal delivery of riboflavin by iontophoresis for the treatment of keratoconus
JP2013066624A (ja) * 2011-09-23 2013-04-18 Menicon Co Ltd イオントフォレーシス用保持具
US20130345615A1 (en) * 2012-06-21 2013-12-26 John W. Higuchi Intracorneal Drug Delivery Device and Associated Methods
WO2014145666A2 (fr) * 2013-03-15 2014-09-18 Avedro, Inc. Traitements de matrices extracellulaires de l'œil
CN108378984B (zh) * 2013-06-25 2020-06-26 Tec晶体有限责任公司 用于眼睛的光线疗法的装置
JP5881083B2 (ja) 2013-08-14 2016-03-09 石根 三井 矯正角膜クロスリンキング用コンタクトレンズ
EP3403693B1 (fr) * 2014-06-27 2020-03-25 Teclens, LLC Dosimétrie acoustique en temps réel pour permettre une réticulation du collagène cornéen

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4273619A1 (fr) * 2022-05-04 2023-11-08 Pauné Fabré, Jaime Lentille de contact orthokératologique

Also Published As

Publication number Publication date
US9664926B2 (en) 2017-05-30
JP2016077873A (ja) 2016-05-16
WO2016056575A1 (fr) 2016-04-14
TWI653038B (zh) 2019-03-11
US20160296368A1 (en) 2016-10-13
EP3045156B1 (fr) 2018-08-22
JP5828535B1 (ja) 2015-12-09
TW201625187A (zh) 2016-07-16
EP3045156A4 (fr) 2017-07-26

Similar Documents

Publication Publication Date Title
EP3045156B1 (fr) Lentille de contact de réticulation de correction de la cornée
US10722401B2 (en) Contact lens for corrective corneal crosslinking and method for producing same
KR101383496B1 (ko) 소프트 콘택트 렌즈
US7591556B2 (en) Scleral contact lens with grooves and method of making lens
US20150277147A1 (en) Therapeutic contact lens
US10564447B2 (en) Contact lens for corrected-cornea crosslinking, corrected-cornea crosslinking method, and ring-shaped contact lens
JP5881083B2 (ja) 矯正角膜クロスリンキング用コンタクトレンズ
US12569672B2 (en) Device, system and method for treating a corneal tissue
CN112236105B (zh) 角膜植入物
JP6120338B2 (ja) リング状角膜矯正用コンタクトレンズ
CA2871343A1 (fr) Lentille intra-corneenne
KR102920637B1 (ko) 링형 렌즈의 제조방법
HK1169715A (en) Soft contact lens
WO2000013630A1 (fr) Flechisseurs corneens
ITMI20072043A1 (it) Dispositivo migliorato per ortocheratologia e metodo per il suo utilizzo
CH709124B1 (it) Apparecchiatura per la correzione della presbiopia.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

17P Request for examination filed

Effective date: 20161005

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

A4 Supplementary search report drawn up and despatched

Effective date: 20170623

RIC1 Information provided on ipc code assigned before grant

Ipc: A61F 9/007 20060101AFI20170619BHEP

Ipc: A61F 9/013 20060101ALI20170619BHEP

Ipc: A61P 27/02 20060101ALI20170619BHEP

Ipc: A61K 31/525 20060101ALI20170619BHEP

Ipc: A61N 5/06 20060101ALI20170619BHEP

Ipc: G02C 7/04 20060101ALI20170619BHEP

Ipc: A61L 27/00 20060101ALI20170619BHEP

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20180308

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1031588

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180915

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015015275

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 4

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG PATENT- UND MARKENANWAELTE, CH

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20180822

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180822

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180822

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181122

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181222

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180822

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181123

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181122

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180822

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180822

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1031588

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180822

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180822

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180822

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180822

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180822

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180822

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180822

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180822

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180822

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180822

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015015275

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180822

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180822

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180822

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20181031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180822

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181007

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

26N No opposition filed

Effective date: 20190523

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181031

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180822

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181007

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181007

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180822

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180822

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180822

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20151007

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180822

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231023

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20231030

Year of fee payment: 9

Ref country code: FR

Payment date: 20231024

Year of fee payment: 9

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20241007

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20241007

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20241031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20241007

REG Reference to a national code

Ref country code: CH

Ref legal event code: U11

Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251101

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20251023

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20251101

Year of fee payment: 11